S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
T   38.24 (-0.60%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.28 (-0.47%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
T   38.24 (-0.60%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.28 (-0.47%)
Log in

Abeona Therapeutics Stock Price, News & Analysis (NASDAQ:ABEO)

$2.25
+0.08 (+3.69 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$2.13
Now: $2.25
$2.29
50-Day Range
$1.54
MA: $2.55
$3.28
52-Week Range
$1.46
Now: $2.25
$10.37
Volume14,627 shs
Average Volume649,601 shs
Market Capitalization$110.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABEO
Previous SymbolOTCMKTS:ACCP
CUSIPN/A
Phone214-665-9495

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$2.80 per share

Profitability

Net Income$-56,670,000.00

Miscellaneous

EmployeesN/A
Market Cap$110.97 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.


Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) posted its quarterly earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.13. View Abeona Therapeutics' Earnings History.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Abeona Therapeutics.

What price target have analysts set for ABEO?

6 brokerages have issued 12-month price objectives for Abeona Therapeutics' stock. Their forecasts range from $4.00 to $29.00. On average, they expect Abeona Therapeutics' stock price to reach $19.67 in the next year. This suggests a possible upside of 774.1% from the stock's current price. View Analyst Price Targets for Abeona Therapeutics.

What is the consensus analysts' recommendation for Abeona Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abeona Therapeutics.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:
  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (10/15/2019)
  • 2. Mizuho analysts commented, "We remain on the sidelines until we can gain more confidence in the company’s execution. Reiterate Neutral / $4 PT." (9/23/2019)
  • 3. Cantor Fitzgerald analysts commented, ": We are reiterating our OW rating and $29 12-month price target on Abeona following 1Q19 earnings. Abeona announced the CMC work for the Phase 3 VITAL study in EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) has been completed. The trial could initiate in mid-2019, following the completion of the last checkbox regarding an ongoing FDA review. While specific timeline guidance has not been provided, pre-screening has begun, which could support a more rapid enrollment. Additionally, the company expects to announce interim data from the Sanfilippo Phase 1/2 studies." (5/14/2019)
  • 4. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a total risk-adjusted net present value (rNPV) of $1.46B to Abeona’s technology platforms, which yields a price per share of $30.00 based on about 48M shares outstanding as of end-2019. We utilize an 85% probability of success for EB-101." (5/6/2019)
  • 5. Maxim Group analysts commented, "Abeona reported positive preclinical data for their AIM vector platform using the AAV204 capsid in cystic fibrosis (CF) and retinal diseases at the American Society of Gene and Cell Therapy and, Association for Research in Vision and Ophthalmology, respectively." (5/1/2019)

Has Abeona Therapeutics been receiving favorable news coverage?

Headlines about ABEO stock have been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abeona Therapeutics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Abeona Therapeutics.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a decrease in short interest in September. As of September 30th, there was short interest totalling 4,670,000 shares, a decrease of 10.2% from the August 30th total of 5,200,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 4.2 days. Currently, 13.5% of the company's stock are short sold. View Abeona Therapeutics' Current Options Chain.

Who are some of Abeona Therapeutics' key competitors?

What other stocks do shareholders of Abeona Therapeutics own?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (2.03%). Company insiders that own Abeona Therapeutics stock include Stefano Buono and Stephen B Howell. View Institutional Ownership Trends for Abeona Therapeutics.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought Abeona Therapeutics stock in the last two years include Stefano Buono and Stephen B Howell. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $2.25.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $110.97 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-56,670,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. View Additional Information About Abeona Therapeutics.

What is Abeona Therapeutics' official website?

The official website for Abeona Therapeutics is http://www.abeonatherapeutics.com/.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]


MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  424 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  704
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe ABEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: What is the yield curve?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel